Patent assignee · KR · COMPANY

Advanced Protein Technologies Corp.

13Patents
10Active
13Granted
58Portfolio score

Filing activity: Feb 12, 1997 → Nov 22, 2023 · 1 expiring within 5 years

Most-cited patents

PatentTitleAreaCited byStatus
US6005073A Process for isolating a protein composition from a muscle source and protein composition Human Necessities 35 Expired
US6451975B1 Protein composition and process for isolating a protein composition from a muscle source Chemistry; Metallurgy 27 Expired
US7473764B2 Protein composition obtained from a muscle source Chemistry; Metallurgy 14 Active
US7771970B2 Process for preparation of polypeptides of interest from fusion polypeptides Chemistry; Metallurgy 2 Expired
US12274708B2 Composition for ameliorating or treating dementia containing 2′-fucosyllactose Human Necessities 0 Active
US10876122B2 Method of producing 2′-fucosyllactose using recombinant Corynebacterium glutamicum Chemistry; Metallurgy 0 Active
US11214808B2 Method of producing 2′-fucosyllactose using fucosyltransferase derived from Pseudopedobacter saltans Chemistry; Metallurgy 0 Active
US12133858B2 Composition for promoting hair growth and improving, preventing, or treating hair loss containing 2′-fucosyllactose as an active ingredient Human Necessities 0 Active
US11753665B2 Method for improving productivity of 2′-fucosyllactose through enzymatic treatment Chemistry; Metallurgy 0 Active
US12168020B2 Method for ameliorating, preventing or treating muscular atrophy or sarcopenia by administering composition comprising 2′-fucosyllactose as active ingredient Human Necessities 0 Active
US11512318B2 Method for producing 3-fucosyllactose using Corynebacterium glutamicum Chemistry; Metallurgy 0 Active
US11980632B2 Antiviral composition containing fucosyllactose as active ingredient Human Necessities 0 Active
US11819510B2 Food composition for ameliorating cerebrovascular diseases containing 2′- fucosyllactose and pharmaceutical composition for preventing or treating cerebrovascular diseases containing 2′-fucosyllactose Human Necessities 0 Active

Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.